Nor Adzimah Johdi, Amanda Seng, Wei-Kang Lee, Hanif Zulkhairi Mohamad Said, Wan Fariza Wan Jamaluddin
{"title":"Exploring Differentially Expressed Genes and Immune Modulation in Diffuse Large B-Cell Lymphoma through RNA Sequencing Analysis.","authors":"Nor Adzimah Johdi, Amanda Seng, Wei-Kang Lee, Hanif Zulkhairi Mohamad Said, Wan Fariza Wan Jamaluddin","doi":"10.30476/IJMS.2023.100149.3234","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Diffuse large B-cell lymphoma (DLBCL) is globally recognized as the most prevalent and aggressive subtype of non-Hodgkin lymphoma. While conventional treatments are effective initially, the disease can become resistant or relapse over time. This study aimed to examine the differentially expressed genes at the transcriptome level and molecular pathways in DLBCL patients.</p><p><strong>Methods: </strong>This investigation utilized RNA sequencing analysis to compare differentially expressed gene samples from five diffuse large B-cell lymphoma patients with two healthy volunteers. These participants were admitted to UKM Medical Center, Kuala Lumpur between 2019 and 2020. The differentially expressed genes were identified using the DESeq2 R package (version 1.10.1) using a negative binomial distribution model. The obtained P values were corrected with the Benjamin and Hochberg method and identified using a False Discovery Rate threshold of <0.05, with log<sub>2</sub> fold change (FC) of ≥2 or ≤-2.</p><p><strong>Results: </strong>Results showed 73 differentially expressed genes between the two groups, among which 70 genes were downregulated, and three genes were upregulated. The differentially expressed genes analyzed with the Reactome pathway were significantly associated with the downregulation of antimicrobial humoral response (P<0.001), neutrophil degranulation (P<0.001), chemokine receptors bind chemokines (P=0.028), defensins (P=0.028) and metabolism of angiotensinogen (P=0.040).</p><p><strong>Conclusion: </strong>These findings suggest that the identified pathways may contribute to cancer progression and weaken the immune response in diffuse large B-cell lymphoma patients. This study offers fresh insights into previously undiscovered downstream targets and pathways modulated by diffuse large B-cell lymphoma.</p>","PeriodicalId":14510,"journal":{"name":"Iranian Journal of Medical Sciences","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11497327/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30476/IJMS.2023.100149.3234","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Diffuse large B-cell lymphoma (DLBCL) is globally recognized as the most prevalent and aggressive subtype of non-Hodgkin lymphoma. While conventional treatments are effective initially, the disease can become resistant or relapse over time. This study aimed to examine the differentially expressed genes at the transcriptome level and molecular pathways in DLBCL patients.
Methods: This investigation utilized RNA sequencing analysis to compare differentially expressed gene samples from five diffuse large B-cell lymphoma patients with two healthy volunteers. These participants were admitted to UKM Medical Center, Kuala Lumpur between 2019 and 2020. The differentially expressed genes were identified using the DESeq2 R package (version 1.10.1) using a negative binomial distribution model. The obtained P values were corrected with the Benjamin and Hochberg method and identified using a False Discovery Rate threshold of <0.05, with log2 fold change (FC) of ≥2 or ≤-2.
Results: Results showed 73 differentially expressed genes between the two groups, among which 70 genes were downregulated, and three genes were upregulated. The differentially expressed genes analyzed with the Reactome pathway were significantly associated with the downregulation of antimicrobial humoral response (P<0.001), neutrophil degranulation (P<0.001), chemokine receptors bind chemokines (P=0.028), defensins (P=0.028) and metabolism of angiotensinogen (P=0.040).
Conclusion: These findings suggest that the identified pathways may contribute to cancer progression and weaken the immune response in diffuse large B-cell lymphoma patients. This study offers fresh insights into previously undiscovered downstream targets and pathways modulated by diffuse large B-cell lymphoma.
背景:弥漫大 B 细胞淋巴瘤(DLBCL)是全球公认的非霍奇金淋巴瘤中发病率最高、侵袭性最强的亚型。虽然常规治疗最初有效,但随着时间的推移,该病可能会出现耐药性或复发。本研究旨在检测DLBCL患者转录组水平的差异表达基因和分子通路:本研究利用 RNA 测序分析比较了五名弥漫大 B 细胞淋巴瘤患者和两名健康志愿者的差异表达基因样本。这些参与者于2019年至2020年期间入住吉隆坡UKM医疗中心。采用负二项分布模型,使用 DESeq2 R 软件包(1.10.1 版)确定了差异表达基因。获得的 P 值用本杰明和霍赫伯格方法进行校正,并使用≥2 或≤-2 的 2 倍变化(FC)的假发现率阈值进行识别:结果显示,两组之间存在73个差异表达基因,其中70个基因下调,3个基因上调。用 Reactome 通路分析的差异表达基因与抗微生物体液反应(PC)的下调显著相关:这些研究结果表明,所发现的通路可能会导致弥漫大B细胞淋巴瘤患者的癌症进展并削弱其免疫反应。这项研究为弥漫大 B 细胞淋巴瘤调节以前未被发现的下游靶点和通路提供了新的见解。
期刊介绍:
The Iranian Journal of Medical Sciences (IJMS) is an international quarterly biomedical publication, which is sponsored by Shiraz University of Medical Sciences. The IJMS intends to provide a scientific medium of communication for researchers throughout the globe. The journal welcomes original clinical articles as well as clinically oriented basic science research experiences on prevalent diseases in the region and analysis of various regional problems.